Regenerative Wound Care Market Report 2026

The regenerative wound care market size has grown strongly in recent years. It will grow from $10.46 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of chronic wounds, a growing geriatric population, rising incidence of diabetes and obesity, expansion of healthcare infrastructure, and increasing awareness about advanced wound care therapies.

The regenerative wound care market size is expected to see strong growth in the next few years. It will grow to $14.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing adoption of regenerative wound care products, rising investment in biotechnology startups, increasing integration of artificial intelligence in wound management, expansion of home healthcare services, and rising demand for personalized wound care solutions. Major trends in the forecast period include technology advancements in bioengineered skin substitutes, innovations in stem cell therapies, developments in growth factor-based treatments, research and developments in scaffold-based wound healing, and technological improvements in wound monitoring devices.

The growing diabetic patient population is expected to drive the growth of the regenerative wound care market in the coming years. This population refers to the rising global prevalence of diabetes mellitus, a chronic condition often associated with complications such as poor circulation and neuropathy, which result in hard-to-heal wounds. Advances in diabetes management and increased awareness have highlighted the need for advanced therapies to prevent complications like foot ulcers. Regenerative wound care supports healing by using bioactive materials and cellular therapies to stimulate tissue repair and closure in complex diabetic wounds. For example, in July 2025, the International Diabetes Federation, a Belgium-based umbrella organization of national diabetes associations, reported that in 2024, diabetes affected 11.10% of the global population, representing 589 million adults, and is projected to rise to 12.95% or 853 million by 2050. Consequently, the growing diabetic patient population is fueling the expansion of the regenerative wound care market.

Major companies in the regenerative wound care market are focusing on technological innovations, such as developing specialized fish-skin graft products processed to preserve their natural structure and omega-3 fatty acids. These advanced grafts are intended for treating complex burn wounds by providing a bioactive scaffold that supports cellular growth and tissue regeneration, while being customized for specific anatomical areas, such as the hands, to enhance application efficiency and functional recovery. For example, in January 2023, Kerecis Limited, an Iceland-based medical device company, launched two new products for the burn market: GraftGuide Mano and GraftGuide Micro. These products use full-thickness fish dermis processed with Kerecis' proprietary EnviroIntact method, which preserves the skin’s original 3D structure and fatty acids. GraftGuide Mano is specifically designed to fit the complex 3D contours of the hand, aiding in the management of second-degree burns.

In August 2023, Coloplast A/S, a Denmark-based medical device company, acquired Kerecis Limited for $1.3 billion. Through this acquisition, Coloplast A/S aimed to expand its wound care portfolio and enhance its position in the biologic tissue regeneration market by incorporating Kerecis’ innovative fish-skin technology into its existing offerings. Kerecis Limited is an Iceland-based medical device company specializing in regenerative wound care.

Major companies operating in the regenerative wound care market are Stryker Corporation, Smith & Nephew plc, Convatec Group plc, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, Angelini Pharma SpA, Organogenesis Holdings Inc., MiMedx Group Inc., Fidia Farmaceutici SpA, Vericel Corporation, BioHorizons IPH Inc., Anika Therapeutics Inc., Kerecis Ltd., AVITA Medical Inc., Aroa Biosurgery Limited, Skye Biologics Inc., Tissue Regenix Group plc, PolarityTE Inc., Regenio, Acelity L.P. Inc.

North America was the largest region in the regenerative wound care market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the regenerative wound care market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regenerative wound care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the regenerative wound care market by increasing costs of imported biological materials, collagen matrices, growth factors, and specialized medical devices used in advanced wound therapies. north america and europe are most affected due to reliance on imported biomaterials and processing equipment, while asia-pacific faces pricing pressure on export-oriented regenerative products. these tariffs are raising treatment costs and affecting procurement budgets for healthcare providers. however, they are also supporting domestic biomaterial production, regional manufacturing capabilities, and local innovation in regenerative wound care technologies.

Regenerative wound care refers to advanced therapeutic approaches that utilize biological materials, cells, growth factors, or bioengineered tissues to stimulate the body’s natural healing processes and repair damaged skin and underlying tissue. It is used to accelerate wound healing, minimize complications, promote tissue regeneration, and improve functional and clinical outcomes in both acute and chronic wounds.

The primary product types of regenerative wound care include autologous stem cells, biological skin substitutes, tissue or multiple tissue platforms, fetal skin, regenerative wound care devices, and other product types. Autologous stem cells include bone-marrow-derived stem cells, adipose-derived stem cells, and peripheral blood stem cells, which are used to promote tissue regeneration and accelerate wound healing. Different wound types treated include chronic wounds, diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers (injuries), acute wounds, surgical and traumatic wounds, and burn wounds. Multiple technologies employed comprise active therapies, scaffold-based therapies, and combination products, and they are used by several end users including hospitals, ambulatory surgical centers, burn care centers and wound clinics, and others.

The regenerative wound care market consists of sales of bioengineered skin substitutes, collagen based wound dressings, growth factor enriched wound care products, stem cell derived wound care therapies, and tissue engineered regenerative wound matrices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.